» Articles » PMID: 33819483

Intestinal Sulfation Is Essential to Protect Against Colitis and Colonic Carcinogenesis

Overview
Specialty Gastroenterology
Date 2021 Apr 5
PMID 33819483
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Sulfation is a conjugation reaction essential for numerous biochemical and cellular functions in mammals. The 3'-phosphoadenosine 5'-phosphosulfate (PAPS) synthase 2 (PAPSS2) is the key enzyme to generate PAPS, which is the universal sulfonate donor for all sulfation reactions. The goal of this study was to determine whether and how PAPSS2 plays a role in colitis and colonic carcinogenesis.

Methods: Tissue arrays of human colon cancer specimens, gene expression data, and clinical features of cancer patients were analyzed. Intestinal-specific Papss2 knockout mice (Papss2) were created and subjected to dextran sodium sulfate-induced colitis and colonic carcinogenesis induced by a combined treatment of azoxymethane and dextran sodium sulfate or azoxymethane alone.

Results: The expression of PAPSS2 is decreased in the colon cancers of mice and humans. The lower expression of PAPSS2 in colon cancer patients is correlated with worse survival. Papss2 mice showed heightened sensitivity to colitis and colon cancer by damaging the intestinal mucosal barrier, increasing intestinal permeability and bacteria infiltration, and worsening the intestinal tumor microenvironment. Mechanistically, the Papss2 mice exhibited reduced intestinal sulfomucin content. Metabolomic analyses revealed the accumulation of bile acids, including the Farnesoid X receptor antagonist bile acid tauro-β-muricholic acid, and deficiency in the formation of bile acid sulfates in the colon of Papss2 mice.

Conclusions: We have uncovered an important role of PAPSS2-mediated sulfation in colitis and colonic carcinogenesis. Intestinal sulfation may represent a potential diagnostic marker and PAPSS2 may serve as a potential therapeutic target for inflammatory bowel disease and colon cancer.

Citing Articles

Study on the potential diagnostic value of metabolomics changes in different biological fluids for aspiration pneumonia.

Chen L, Chen Y, Lin F, Wang J, Gao H, Liu Y BMC Pulm Med. 2025; 25(1):60.

PMID: 39905415 PMC: 11792630. DOI: 10.1186/s12890-025-03519-x.


Bile Acids in Inflammatory Bowel Disease: From Pathophysiology to Treatment.

Bai S, Chandnani A, Cao S Biomedicines. 2025; 12(12).

PMID: 39767816 PMC: 11673883. DOI: 10.3390/biomedicines12122910.


The dichotomous roles of microbial-modified bile acids 7-oxo-DCA and isoDCA in intestinal tumorigenesis.

Dong X, Sun F, Secaira-Morocho H, Hui A, Wang K, Cai C Proc Natl Acad Sci U S A. 2024; 121(47):e2317596121.

PMID: 39531490 PMC: 11588130. DOI: 10.1073/pnas.2317596121.


Microbial assimilatory sulfate reduction-mediated HS: an overlooked role in Crohn's disease development.

Luo W, Zhao M, Dwidar M, Gao Y, Xiang L, Wu X Microbiome. 2024; 12(1):152.

PMID: 39152482 PMC: 11328384. DOI: 10.1186/s40168-024-01873-2.


Gut microbiota metabolite indole-3-acetic acid maintains intestinal epithelial homeostasis through mucin sulfation.

Li M, Ding Y, Wei J, Dong Y, Wang J, Dai X Gut Microbes. 2024; 16(1):2377576.

PMID: 39068517 PMC: 11285290. DOI: 10.1080/19490976.2024.2377576.


References
1.
Murphy N, Moreno V, Hughes D, Vodicka L, Vodicka P, Aglago E . Lifestyle and dietary environmental factors in colorectal cancer susceptibility. Mol Aspects Med. 2019; 69:2-9. DOI: 10.1016/j.mam.2019.06.005. View

2.
Li G, Liu D, Kimchi E, Kaifi J, Qi X, Manjunath Y . Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice. Gastroenterology. 2018; 154(4):1024-1036.e9. PMC: 5908238. DOI: 10.1053/j.gastro.2017.10.050. View

3.
Gendler S, Spicer A . Epithelial mucin genes. Annu Rev Physiol. 1995; 57:607-34. DOI: 10.1146/annurev.ph.57.030195.003135. View

4.
Johansson M, Gustafsson J, Holmen-Larsson J, Jabbar K, Xia L, Xu H . Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut. 2013; 63(2):281-91. PMC: 3740207. DOI: 10.1136/gutjnl-2012-303207. View

5.
Gadaleta R, Garcia-Irigoyen O, Moschetta A . Bile acids and colon cancer: Is FXR the solution of the conundrum?. Mol Aspects Med. 2017; 56:66-74. DOI: 10.1016/j.mam.2017.04.002. View